Literature DB >> 28652214

Elevated levels of von Willebrand factor and high mobility group box 1 (HMGB1) are associated with disease severity and clinical outcome of scrub typhus.

Hongliu Chen1, Zong Ning1, Ying Qiu1, Yuanli Liao1, Haihua Chang1, Yuanyuan Ai1, Yinghua Wei2, Yiming Deng2, Ying Shen3.   

Abstract

OBJECTIVES: This study aimed to investigate whether von Willebrand factor (vWF) and high mobility group box 1 (HMGB1) are associated with the severity and clinical outcome of scrub typhus and to seek novel biomarkers for surveillance and prediction of the prognosis of this infection.
METHODS: Serum concentrations of vWF and HMGB1 were measured twice by ELISA for scrub typhus patients (n=103), once prior to doxycycline therapy and then on day 7 of doxycycline therapy; concentrations were measured once for healthy controls (n=32).
RESULTS: Among the total 103 patients enrolled, 38 had disease complicated by multiple organ dysfunction syndrome (MODS). Serum concentrations of vWF and HMGB1 were significantly higher in all the patients than in the healthy controls, both prior to doxycycline treatment and on day 7 of doxycycline treatment (p<0.01). Furthermore, serum levels of vWF, HMGB1, and creatinine (SCr) in the patients with MODS increased distinctly, while the platelet (PLT) count diminished markedly compared to the levels in patients without MODS (p<0.01). The concentration of vWF was positively correlated with that of HMGB1 (r=0.764, p<0.001) and SCr (r=0.528, p<0.001), but negatively correlated with the PLT count (r=-0.632, p<0.001). Both HMGB1 and vWF were significantly associated with mortality in scrub typhus (area under the curve (AUC)=0.864, p=0.001, and AUC=0.862, p=0.001, respectively).
CONCLUSIONS: Elevated levels of vWF and HMGB1 are associated with the severity and clinical outcome of scrub typhus. These represent possible new biomarkers for use in the assessment and prognostic prediction of this infection.
Copyright © 2017 The Author(s). Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  High mobility group box 1; Multiple organ dysfunction syndrome; Scrub typhus; von Willebrand factor

Mesh:

Substances:

Year:  2017        PMID: 28652214     DOI: 10.1016/j.ijid.2017.06.015

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN: 1201-9712            Impact factor:   3.623


  6 in total

1.  Inorganic Polyphosphate Amplifies High Mobility Group Box 1-Mediated Von Willebrand Factor Release and Platelet String Formation on Endothelial Cells.

Authors:  Indranil Biswas; Sumith R Panicker; Xiaofeng Cai; Padmaja Mehta-D'souza; Alireza R Rezaie
Journal:  Arterioscler Thromb Vasc Biol       Date:  2018-08       Impact factor: 8.311

Review 2.  Dysregulated Th1 Immune and Vascular Responses in Scrub Typhus Pathogenesis.

Authors:  Lynn Soong
Journal:  J Immunol       Date:  2018-02-15       Impact factor: 5.422

3.  HMGB1, anti-HMGB1 antibodies, and ratio of HMGB1/anti-HMGB1 antibodies as diagnosis indicator in fever of unknown origin.

Authors:  Mingkun Chen; Li Zhu; Miao Xue; Rongrong Zhu; Liling Jing; Huaizhou Wang; Yanghua Qin
Journal:  Sci Rep       Date:  2021-03-03       Impact factor: 4.379

4.  Predictors of Mortality in Scrub Typhus Infection Requiring Intensive Care Admission in Tertiary Healthcare Centre of Nepal.

Authors:  Shital Adhikari; Ramesh Sharma Poudel; Shakti Shrestha; Praves Lamichhane
Journal:  Interdiscip Perspect Infect Dis       Date:  2018-06-03

5.  The validity of diagnostic cut-offs for commercial and in-house scrub typhus IgM and IgG ELISAs: A review of the evidence.

Authors:  Kartika Saraswati; Meghna Phanichkrivalkosil; Nicholas P J Day; Stuart D Blacksell
Journal:  PLoS Negl Trop Dis       Date:  2019-02-04

6.  Systematic review of the scrub typhus treatment landscape: Assessing the feasibility of an individual participant-level data (IPD) platform.

Authors:  Kartika Saraswati; Brittany J Maguire; Alistair R D McLean; Sauman Singh-Phulgenda; Roland C Ngu; Paul N Newton; Nicholas P J Day; Philippe J Guérin
Journal:  PLoS Negl Trop Dis       Date:  2021-10-14
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.